Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023418 (leukemia)
 93,477 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Adult T cell leukaemia-lymphoma (ATL) was first discovered and reported in Japan, where it has a high incidence in the south-west region. The first human retrovirus HTLV-I (human T-cell lymphotropic virus type I) is considered to be related to its aetiology. In ATL endemic areas, HTLV-I carriers form a fairly high percentage of the population, even among healthy individuals. ATL shows diverse clinical features. It can be divided into four subtypes: acute, chronic, smouldering and lymphoma type. ATL cells originate from the CD4-positive subset of peripheral T cells; they show a characteristic notch in the nucleus and a tendency to lobulation. ATL resists chemotherapy, and patients with acute and lymphoma types have a fairly poor prognosis. A definite diagnosis of ATL is made by documenting the presence of HTLV-I proviral DNA in the DNA of tumour cells. HTLV-I infection is caused by transmission of live lymphocytes via three routes (from mother to child, from males to females, and by transfusion). Familial occurrence of ATL is frequently seen. HTLV-I infection is seen in other countries, but its incidence is highest in Japan. Infection with HTLV-I is a direct cause of ATL. Furthermore, infection with this virus can indirectly cause many other diseases via the induction of immunodeficiency, such as chronic lung disease, opportunistic lung infection, cancer of other organs, monoclonal gammopathy, chronic renal failure, strongyloidiasis, non-specific dermatomycosis, HTLV-I-associated lymphadenitis, HTLV-I uveitis and HTLV-I-associated myelopathy-tropical spastic paraparesis (HAM/TSP).
 ...
PMID:Adult T cell leukaemia-lymphoma. 803 96

Mucormycosis is an opportunistic fungal infection that commonly begins by invading the respiratory tract. The purpose of the present study was to define the clinical presentation of pulmonary mucormycosis and to evaluate current treatment regimens. Thirty patients treated at our institution and 225 cases reported in the literature were reviewed. For the combined groups, the mean age at presentation was 41 +/- 21 years and associated medical conditions included leukemia or lymphoma (37%), diabetes mellitus (32%), chronic renal failure (18%), history of organ transplantation (7.6%), or a known solid tumor (5.6%). The in-hospital mortality was 65% for patients with isolated pulmonary mucormycosis, 96% for those with disseminated disease, and 80% overall. The mortality in patients treated surgically was 11%, significantly lower than the 68% mortality in those treated medically (p = 0.0004). The most common causes of death were fungal sepsis (42%), respiratory insufficiency (27%), and hemoptysis (13%). Pulmonary mucormycosis has a high mortality; however, antifungal agents appear to improve survival. In addition, surgical resection may provide additional benefit to patients with pulmonary mucormycosis confined to one lung.
 ...
PMID:Pulmonary mucormycosis: results of medical and surgical therapy. 816 12

A fully automated reticulocyte counter, Sysmex R-1000 has been evaluated at three Norwegian hospitals. The instrument measures fluorescence-labelled RNA in the reticulocytes by flow cytometry. It also generates information on reticulocyte maturity. Instrument precision was superior to that achieved with the routine visual counting method. Samples preserved at room temperature remain stable for one day, whereas samples preserved at 5 degrees C remain stable for four days. An increasing number of reticulocytes is often the first sign of marrow regeneration after bone marrow transplantation or treatment of leukaemia with cytostatica. In patients with chronic renal failure who are receiving erythropoietin, the increase in reticulocytes is seen within days, and precedes the increase in haemoglobin by 2-3 weeks.
 ...
PMID:[Reticulocytes--new possibilities with automated counting]. 846 34

Disseminated infection with the rapidly growing mycobacteria Mycobacterium chelonae and Mycobacterium fortuitum is uncommon. Only eight cases were diagnosed at Duke University Medical Center (Durham, NC) over the last 14 years. We identified 46 other cases by review of the medical literature since 1960. We categorized these 54 cases into three groups according to underlying disease and outcome. Group 1 comprised patients with no identified immune defect, a kidney transplant, collagen vascular disease, or chronic renal failure; these patients usually presented with skin involvement and responded well to antimicrobial therapy (survival rate, 90%). Group 2 comprised patients with cell-mediated immune deficiency, lymphoma, or leukemia; they presented with widespread, multiorgan involvement and severe illness. The survival rate in this group was only 10%. Patients in group 3 (who had other underlying diseases) had intermediately severe illnesses and intermediate responses to therapy. These groups provide the basis for an understanding of disseminated infection secondary to rapidly growing mycobacteria and of the profound effect that unresolved immunosuppression has on survival.
 ...
PMID:Disseminated infection with rapidly growing mycobacteria. 851 48

Healthy DHCWs do not seem to be at significantly higher risk for occupationally acquired diseases when compared with other HCWs. Special attention should be paid to DHCWs who are more susceptible to diseases potentially transmitted in a dental setting. These DHCWs include pregnant women, due to their immunologic changes, and the developing fetus; DHCWs; those with habits such as excessive intake of alcohol; DHCWs following splenectomy, radiotherapy, and long-term corticosteroid therapy; and DHCWs suffering from diseases that have an impact on the first and secondary defense against infections, such as diabetes mellitus, chronic renal failure, sickle cell anemia, leukemia, lymphoma, or HIV.
 ...
PMID:Dental health care workers at risk. 864 21

Recombinant erythropoietin (r-HuEPO) was the first growth factor introduced into clinical practice. The main indication for its therapeutic use remains treatment of anaemias during chronic renal failure. In Czech Republic it is at present administered to 55% of patients included in a regular haemodialyzation program and in the pre-dialyzation stage of the disease, consistent with European practice. In addition to a marked improvement of the quality of life, during r-HuEPO treatment also the prevalence of some cardiovascular complications is reduced and immune functions improve. The list of diseases where r-HuEPO therapy is indicated has been, however, extended nowadays. A very favourable effect was recorded in some haematological malignicies and solid tumours. The best results were observed so far in the treatment of anaemia associated with multiple myeloma and chronic lymphatic leukaemia, and also in malignant lymphomas, carcinoma of the breast and ovary. It is used also in the treatment of suppressed erythropoiesis resulting from cytoreducing therapy. Other indications include anaemia after transplantations of bone marrow, preparation before autologous transfusions and some cases of myelodysplastic syndrome. The authors mention also other contemporary possibilities of r-HuEPO use.
 ...
PMID:[Erythropoietin in the treatment of anemias]. 868 10

Measurements of the antithrombin III (AT III) activity in feline plasma with a thrombin dependent chromogenic substrate assay using an automatic analyzer showed a high within run precision. The coefficient of variance was 1.82% (normal AT III activity) or 3.19% (decreased AT III activity), respectively. In comparison with the feline pool plasma the AT III activity in canine plasma was similar (93.7%) and in human reference plasma was lower (71.7%). Respecting healthy cats aged more than three months no distinct influence could be demonstrated on the AT III activity neither of age nor of gender (p = 0.2180). Based on the 2.5%- and 97.5%- quantile the reference range was 83.5-122.5% respecting the total number of healthy cats (n = 138) or 82.6-121.5% concerning the 116 European Shorthair cats. AT III activity of cats infected with feline immunodeficiency virus (n = 37) or teline leukemia virus (n = 20) as well as of cats suffering from different solitary tumors (n = 8) was not distinctly different from the control group (p > 0.05). On the contrary, a significant decrease of AT III activity was found in traumatized cats (n = 20; median = 80.8%, p < 0.0001) as well as in animals with chronic renal failure (n = 20; median = 91.7%, p = 0.0228) which can be mainly attributed to a consumption reaction or excessive renal loss, respectively.
 ...
PMID:[Antithrombin III activity in health cats and its changes in selected disease]. 945 44

A 66-year-old woman who suffered from chronic glomerulonephritis had been undergoing hemodialysis for about 10 years. A reddish papule on her waist developed gradually into a nodule (1.9 x 1.4 cm). Histopathological findings showed that the tumor cells had oval to reniform nuclei; multinucleated neoplastic cells and erythrophagocytosis were also present. Immunohistochemical analyses revealed that the membranes of the tumor cells stained for Ber-H2 (Ki-1) and epithelial membrane antigen (EMA), Vimentin was partially positive, but keratin, S-100, chromogranin, leukocyte common antigen (LCA), UCHL-1, MT-1, L-26, MB-1 and C3D-1 were all negative. Anti-human T-cell leukemia virus-1 (HTLV-1) was also negative. No gene rearrangement of the T-cell receptors beta-, gamma- and delta-chain could be detected. From these results, we diagnosed cutaneous Ki-1 anaplastic large cell lymphoma (ALCL), but the origin could not be determined. The relationship between lymphoma and chronic renal failure and/or hemodialysis was far from clear.
 ...
PMID:A case of cutaneous Ki-1 positive anaplastic large cell lymphoma in a hemodialysed patient. 957 83

We encountered 64 patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia between April 1993 and March 1994. Mean patient age was 54 years. There were 46 males and 18 females. Underlying diseases mainly consisted of traffic accident (10 patients), valvular heart disease (5 patients), chronic renal failure (5 patients), leukemia (5 patients), pneumonia (3 patients), and malignant lymphoma (3 patients). The common clinical laboratory findings of MRSA bacteremia included decreses in total protein, albumin and hemoglobin as well as increases in white blood cells (neutrophils) and C reactive protein. In particular, an increase in C reactive protein by 10 mg/dl or more may be useful for diagnosing bacteremia. Laboratory findings were compared between surviving and non-surviving patients. There were significant differences in albumin, cholesterol, bilirubin, creatinine, and CRP. In 18 patients (28.1%), bacteremia was caused by infection due to contamination of central venous catheters. Since medical treatment with intra-vascular devices may cause bacteremia, sufficient caution is needed.
 ...
PMID:Studies on Methicillin-Resistant Staphylococcus aureus Bacteremia Due to Laboratory Medical Analysis. 1003 83

Patients with multiple myeloma (MM) and chronic renal failure have generally been excluded from myeloablative therapy programs followed by hematopoietic stem cell support because of the potential increase in transplant-related morbidity and mortality. We here report our experience treating six MM patients with moderate to severe renal insufficiency, with autologous stem cell transplantation. One of these patients required chronic hemodialysis since the diagnosis of MM was made. Peripheral blood stem cell collection was performed with either cyclophosphamide 5.5-7 g/m2 + G-CSF, 5 microg/kg/day (patients 1-3, 5 and 6) or G-CSF, 15 microg/kg/day alone (patient No. 4). Four patients (Nos 1-4) received autotransplant as front-line therapy, while the last two patients were treated in relapse, which occurred following prior autologous stem cell transplantation in support of melphalan, 200 mg/m2 (No. 5) or maintainance therapy with alpha-interferon (No. 6). High-dose chemotherapy administered as preparation to transplant included busulfan 12 mg/kg + melphalan 80 mg/m2 (patients 1-3 and 6) or melphalan 80 mg/m2 alone (patients 4 and 5) in order to reduce mucosal damage. Following transplant, prompt and sustained recovery of hematopoiesis was documented in all the patients; 500 PMN/microI and 20000 platelets/microI were reached after a median of 13 and 14 days, respectively. None of the patients suffered from WHO grade 3-4 infectious complications. Transplant-related toxicity included grade 3-4 oral mucositis (patients 1, 4 and 5) and veno-occlusive disease (patient No. 3). Renal function either improved or remained stable throughout the transplant period. All the patients but one responded to therapy, three of them are progression free after 2, 15 and 26 months; two relapsed after 16 and 4 months and one died from cholangiocarcinoma 7 months after transplant, while still in remission. Although our experience is limited so far, these results appear promising and support the investigational use of myeloablative therapy in MM patients with chronic renal failure.
Leukemia 2000 Jul
PMID:Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. 1091 57


<< Previous 1 2 3 4 5 Next >>